NovaBridge Biosciences (NBP) Notes Payables (2022 - 2023)

NovaBridge Biosciences (NBP) has reported Notes Payables for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Notes Payables rose 56.17% year-over-year to $4.2 million; the TTM figure through Dec 2023 stood at $4.2 million (up 56.17% YoY), while the FY2023 annual figure was $4.2 million, down 99.85% from the prior year.
• Notes Payables rose to $4.2 million in Q4 2023 per NBP's latest filing, from $4.1 million in the prior quarter.
• Across five years, Notes Payables topped out at $7.1 million in Q4 2019 and bottomed at $2.7 million in Q4 2022.
• Historically, Notes Payables has averaged $4.5 million across 3 years, with a median of $4.1 million in 2023.
• Annual changes were most pronounced in 2019 — Notes Payables tumbled 38.69% — and 2023, when it jumped 56.17%.
• NovaBridge Biosciences' Notes Payables stood at $7.1 million in 2019, then plunged by 62.43% to $2.7 million in 2022, then surged by 56.17% to $4.2 million in 2023.
• Business Quant data shows NBP's Notes Payables at $4.2 million in Q4 2023, $4.1 million in Q2 2023, and $2.7 million in Q4 2022.